Drug Profile
Ecraprost
Alternative Names: Circulase™Latest Information Update: 06 Jun 2006
Price :
$50
*
At a glance
- Originator Mitsubishi Pharma Corporation
- Class Prostaglandins
- Mechanism of Action Prostaglandin E1 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Diabetic neuropathies; Intermittent claudication; Peripheral arterial disorders; Peripheral arterial occlusive disorders; Reperfusion injury
Most Recent Events
- 11 May 2006 Discontinued - Phase-II for Peripheral arterial occlusive disorders in Japan (unspecified route)
- 11 May 2006 Discontinued - Phase-III for Peripheral arterial occlusive disorders in USA (unspecified route)
- 06 Dec 2004 This compound is still in active development for Peripheral Arterial Occlusive Disorders